PRL3-ZUMAB

Phase 2Monoclonal antibody

IIntra-IMMUSG Pte Ltd

PRL3-ZUMAB is one of 115 biologic programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

Patients With Solid TumorsActive, not recruiting

Advanced Solid TumorsRecruiting

Solid TumorPhase 1

Active, not recruiting

Patients With Solid TumorsPhase 2

Active, not recruiting

Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

PRL3-ZUMAB

IIntra-IMMUSG Pte Ltd

Phase 2

4 2

Yervoy

Bristol-Myers Squibb

Preclinical

3 3

Fludara

Sanofi

Preclinical

1 4

DATROWAY

Daiichi Sankyo

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 6

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Tulmimetostat

Novartis

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 10

Sacituzumab Govitecan-Hziy

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Study completion

NCT03191682

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors

Recruiting·NNational Cancer Centre, Singapore·Phase 2·NCT04118114·30 enrolled

Patients With Solid Tumors1 trial

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Active, not recruiting·IIntra-IMMUSG Pte Ltd·Phase 2·NCT04452955·51 enrolled

Advanced Solid Tumor1 trial

Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients

Recruiting·IIntra-IMMUSG Pte Ltd·Phase 2/3·NCT07290088·52 enrolled

Unspecified1 trial

A First-in-Human Study of PRL3-ZUMAB

Active, not recruiting·NNational University Hospital, Singapore·Phase 1·NCT03191682·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for PRL3-ZUMAB. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRL3-ZUMAB compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRL3-ZUMAB. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Intra-IMMUSG Pte Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: IIntra-IMMUSG Pte Ltd

PRL3-ZUMAB

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Advanced Solid Tumors1 trial

Patients With Solid Tumors1 trial

Advanced Solid Tumor1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News